Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 3/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.34 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.34 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.34 |
| ▸ | PDE6D | O43924 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 2/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4087554 | 0.82 | CYP4A11 (0.45) | NPC1RAB9ACYP4A11AKT1CYP4F2 | |
| SCHEMBL4944026 | 0.74 | AKT1 (0.44) | NPC1RAB9ACYP4A11AKT1CYP4F2 | |
| SCHEMBL4946101 | 0.74 | CYP4A11 (0.46) | NPC1CYP4A11MGLLAKT1CYP4F2 | |
| SCHEMBL4944311 | 0.71 | CYP4A11 (0.43) | NPC1CYP4A11AKT1CYP4F2 | |
| SCHEMBL17064275 | 0.69 | LMNA (0.45) | NPC1CASP1RAB9ACYP4A11CYP4F2 | |
| SCHEMBL1402913 | 0.69 | AKT1 (0.52) | NPC1RAB9ACYP4A11AKT1CYP4F2 | |
| SCHEMBL6665900 | 0.68 | RAB9A (0.55) | DGKANPC1CASP1RAB9ACYP4A11 | |
| SCHEMBL12971158 | 0.68 | RAB9A (0.64) | DGKANPC1CASP1RAB9AMGLL | |
| SCHEMBL23912343 | 0.67 | CYP4A11 (0.60) | CYP4A11CYP4F2 | |
| SCHEMBL19078982 | 0.67 | CYP4A11 (0.50) | THRATHRBCYP4A11PDE6DCYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531533-B2 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| EP-1847533-A1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | WNT1, CYP11B2, CYP11B1 | DGKA 3003/4885NPC1 3052/4885CASP1 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.